Journal of Clinical Endocrinology & Metabolism, Vol 68, 135-140, Copyright © 1989 by Endocrine Society

ARTICLES

Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin

AM Suikkari, VA Koivisto, R Koistinen, M Seppala and H Yki-Jarvinen
First Department of Obstetrics and Gynecology, University Central Hospital, Helsinki, Finland.

We previously demonstrated that supraphysiological insulin concentrations reduced the plasma 34K insulin-like growth factor- binding protein (IGF-BP) concentrations in humans. In this study we examined whether physiological changes in plasma insulin concentrations regulate IGF-BP and, if so, whether the regulation is influenced by race, glucose tolerance, or rate of glucose metabolism. For these purposes we 1) analyzed the relationship between fasting plasma insulin and IGF-BP concentrations in 2 racial groups (23 caucasians and 35 southwestern American Indians), 2) measured the response of plasma IGF- BP to oral glucose in 20 normal subjects, and 3) determined the dose- response characteristics of plasma IGF-BP to glucose and insulin in 23 normal subjects at 4 different insulin and glucose concentrations. The fasting plasma insulin concentration was inversely related to the plasma IGF-BP concentration in both the caucasian and Indian groups (P less than 0.0001). In the caucasian group the mean plasma IGF-BP concentration was higher [15 +/- 4 (+/- SE) micrograms/L] than in the Indian group (8 +/- 2 micrograms/L; P less than 0.05). This difference was independent of race and glucose tolerance, and it could be explained by lower plasma insulin concentrations in the caucasian (387 +/- 50 pmol/L) than in the Indian group (215 +/- 43 pmol/L; P less than 0.001). After oral glucose administration, the insulin concentration (423 +/- 72 pmol/L) was maximal 30 min after glucose treatment, and significant suppression of the IGF-BP concentration occurred at 90 min. Analysis of the dose-response curves revealed maximal suppression of IGF-BP at about 1150 pmol/L insulin, and half-maximal suppression at about 290 pmol/L. The plasma glucose concentration or the rate of glucose metabolism had no effect on the IGF-BP concentration. These data suggest that insulin is a major regulator of plasma IGF-BP concentrations under physiological conditions.

This article has been cited by other articles:

				C. D Wright, R. J Orbus, T. R H Regnault, and R. V Anthony Effects of early gestation GH administration on placental and fetal development in sheep J. Endocrinol., July 1, 2008; 198(1): 91 - 99. [Abstract] [Full Text] [PDF]

				Y. Takemura, Y. Osuga, M. Harada, T. Hirata, K. Koga, C. Morimoto, Y. Hirota, O. Yoshino, T. Yano, and Y. Taketani Serum adiponectin concentrations are decreased in women with endometriosis Hum. Reprod., December 1, 2005; 20(12): 3510 - 3513. [Abstract] [Full Text] [PDF]

				D. J. Jakubowicz, P. A. Essah, M. Seppala, S. Jakubowicz, J.-P. Baillargeon, R. Koistinen, and J. E. Nestler Reduced Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein-1 in Women with Polycystic Ovary Syndrome during First Trimester of Pregnancy J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 833 - 839. [Abstract] [Full Text] [PDF]

				M. J. de Souza, J. Van Heest, L. M. Demers, and B. L. Lasley Luteal Phase Deficiency in Recreational Runners: Evidence for a Hypometabolic State J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 337 - 346. [Abstract] [Full Text] [PDF]

				A. L. Ogilvy-Stuart, M. A. Soos, S. J. Hands, M. Y. Anthony, D. B. Dunger, and S. O'Rahilly Hypoglycemia and Resistance to Ketoacidosis in a Subject without Functional Insulin Receptors J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3319 - 3326. [Abstract] [Full Text] [PDF]

				G. A. Lincoln, S. M. Rhind, S. Pompolo, and I. J. Clarke Hypothalamic control of photoperiod-induced cycles in food intake, body weight, and metabolic hormones in rams Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R76 - R90. [Abstract] [Full Text] [PDF]

				D. J. Jakubowicz, M. Seppälä, S. Jakubowicz, O. Rodriguez-Armas, A. Rivas-Santiago, H. Koistinen, R. Koistinen, and J. E. Nestler Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1126 - 1133. [Abstract] [Full Text]

				O. Ogueh, J.P. Miell, J.C. Jones, J.S. Jones, J. Alaghband-Zadeh, and M.R. Johnson Antenatal dexamethasone and the growth hormone-insulin-like growth factor axis Hum. Reprod., June 1, 2000; 15(6): 1403 - 1406. [Abstract] [Full Text] [PDF]

				H.-S. Wang, T.-H. Wang, and Y.-K. Soong Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy Hum. Reprod., January 1, 2000; 15(1): 50 - 54. [Abstract] [Full Text] [PDF]

				P. Vuguin, B. Linder, R. G. Rosenfeld, P. Saenger, and J. DiMartino-Nardi The Roles of Insulin Sensitivity, Insulin-Like Growth Factor I (IGF-I), and IGF-Binding Protein-1 and -3 in the Hyperandrogenism of African-American and Caribbean Hispanic Girls with Premature Adrenarche J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2037 - 2042. [Abstract] [Full Text]

				A. L. Ogilvy-Stuart, S. J. Hands, C. J. Adcock, J. M. P. Holly, D. R. Matthews, V. Mohamed-Ali, J. S. Yudkin, A. R. Wilkinson, and D. B. Dunger Insulin, Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1, Growth Hormone, and Feeding in the Newborn J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3550 - 3557. [Abstract] [Full Text]

				M. E. Wilson Regulation of the Growth Hormone-Insulin-Like Growth Factor I Axis in Developing and Adult Monkeys Is Affected by Estradiol Replacement and Supplementation with Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2018 - 2028. [Abstract] [Full Text]

				N. Attia, W. V. Tamborlane, R. Heptulla, D. Maggs, A. Grozman, R. S. Sherwin, and S. Caprio The Metabolic Syndrome and Insulin-Like Growth Factor I Regulation in Adolescent Obesity J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1467 - 1471. [Abstract] [Full Text]

				G. A. Laughlin, C. E. Dominguez, and S. S. C. Yen Nutritional and Endocrine-Metabolic Aberrations in Women with Functional Hypothalamic Amenorrhea J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 25 - 32. [Abstract] [Full Text]

				D. Haffner, W. F. Blum, U. Heinrich, O. Mehls, and B. Tonshoff Impaired Postprandial Regulation of Insulin-Like Growth Factor Binding Protein-1 in Children with Chronic Renal Failure J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2832 - 2835. [Abstract] [Full Text] [PDF]

				E. Fernqvist-Forbes, A. Hilding, K. Ekberg, and K. Brismar Influence of Circulating Epinephrine and Norepinephrine on Insulin-Like Growth Factor Binding Protein-1 in Humans J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2677 - 2680. [Abstract] [Full Text] [PDF]

				J. P. Holden, T. L. Butzow, G. A. Laughlin, M. Ho, A. J. Morales, and S. C. Yen Regulation of Insulin-Like Growth Factor Binding Protein-I During the 24-Hour Metabolic Clock and in Response to Hypoinsulinemia Induced by Fasting and Sandostatin in Normal Women Reproductive Sciences, January 1, 1995; 2(1): 38 - 44. [Abstract] [PDF]